HMG 150 IU

HMG 150 IU contains human menopausal gonadotropin, which is FDA-approved for fertility treatment in both men and women. In men, it is used to stimulate spermatogenesis in hypogonadotropic hypogonadism when HCG alone has failed to restore adequate sperm production. In non-medical bodybuilding contexts, HMG is sometimes referenced in post-cycle recovery protocols, though such use falls outside approved indications.

Clinical fertility protocols for male infertility typically use 75–150 IU every other day alongside ongoing HCG therapy. For female fertility treatment, dosing is individualized by a physician based on ovarian response monitoring. Community recovery protocols commonly reference 75 IU every other day for 1–2 weeks.

HMG is itself sometimes used as a component of post-cycle therapy rather than requiring PCT afterward. In non-medical contexts, HMG is typically used alongside HCG 5000 IU to provide FSH stimulation in addition to LH-like activity. Some protocols also include selective estrogen receptor modulators such as Clomid or Nolvadex.

HMG contains both FSH and LH activity. The FSH component stimulates Sertoli cells in the testes, supporting spermatogenesis, while the LH component stimulates Leydig cells to produce testosterone. This dual activity makes HMG uniquely valuable for fertility applications where both sperm production and testosterone support are needed.

HMG's FSH component has a half-life of approximately 30 hours, and steady-state levels are reached after approximately 3–5 days of consecutive injections. However, meaningful spermatogenic recovery requires 72–90 days per cycle, so clinical fertility protocols typically continue for 3–12 months.

There is no single compound that is universally best for recovery. HMG provides both FSH and LH activity, while HCG 5000 IU provides primarily LH-like activity. Clinical studies show that combination therapy with HCG and HMG produces higher maximum testosterone levels than HCG alone. The appropriate approach depends on individual circumstances and goals.

HMG contains both FSH and LH activity, while HCG primarily mimics LH activity only. The FSH component in HMG provides stimulation of Sertoli cells for spermatogenesis, which HCG cannot do. This is why clinical protocols add HMG when HCG alone has failed to restore adequate sperm production.

HMG directly provides FSH and LH activity at the gonadal level, while Clomid works indirectly by blocking estrogen feedback at the hypothalamus and pituitary, increasing endogenous gonadotropin release. HMG's effects do not depend on a functioning hypothalamic-pituitary axis, while Clomid's do.

150 IU is a standard clinical dose used in female fertility treatment, typically as a starting dose before titration based on ovarian response. For male fertility protocols, 75–150 IU every other day is commonly referenced. Doses are individualized based on indication and clinical response.

HMG 150 IU is labeled at 150 IU of human menopausal gonadotropin per vial. It is supplied as a lyophilized powder in a 2 mL vial, requiring reconstitution before use.

No published laboratory report is currently available for this specific product. Product potency and purity verification would apply to tested samples only and should not be interpreted as a measurement of every vial or production batch.

Lyophilized HMG is typically reconstituted with the diluent provided or a suitable solvent such as Bacteriostatic Water. The product should be used right after mixing, and unused reconstituted solution should be discarded. Proper sterile technique should be used during reconstitution.